CD74 and plasma cell myeloma: Therapeutic monoclonal antibodies targeting MIF (imalumab) and its canonical receptor CD74 (milatuzumab) have been developed, with milatuzumab achieving orphan drug designation from the FDA for the treatment of multiple myeloma (52).